ECOG-ACRIN BY THE NUMBERS

Loading Quotes...

News and Announcements

NCI-MATCH trial enrolling an average of 7-8 new patients weekly; positive findings from substudy Y presented, read press release

President, American Society of Hematology

Martin S. Tallman, MD
Hematologic Oncologist and Chief, Leukemia Service

Memorial Sloan Kettering Cancer Center

Congratulations to Dr. Tallman, who chaired the ECOG-ACRIN Leukemia Committee for 16 years. Dr. Tallman will serve a one-year term as vice president of ASH, starting in December, followed by successive terms as president-elect and president.

We acknowledge Dr. Tallman for his tremendous leadership of the Leukemia Committee during his tenure from 1997-2013. Practice-changing studies in AML and other acute and chronic leukemias occurred during this time, and he greatly enhanced the scientific structure that supports the committee’s activities to this day.

Achievement Award in Medicine

Edith Peterson Mitchell
Brigadier General USAF (Retired), MD, FACP, FCPP
Clinical Professor of Medicine and Medical Oncology
Thomas Jefferson University

Congratulations to Dr. Mitchell, a long-standing member of ECOG-ACRIN and a national champion for health equity in cancer clinical trials, for this recognition. The award honors a Jefferson physician who has embraced Jefferson’s mission, provided exemplary care to their patients, and has been a recognized leader in their field.

Meet the 2018 Young Investigator Symposium presenters here

The E2112 study recently reached its enrollment goal! Learn more about the trial for men and women with advanced breast cancer, here

Results of TAILORx released, read press release

Results of NCI-MATCH (EAY131) Arms I, Q, and W released, read press release

Webinar on patient-reported outcomes research by David Cella, PhD, available here

New Trials in 2018

October 3, 2018

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

EA9171 trial info here

October 1, 2018

Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

EA6174 trial info here

July 23, 2018

Understanding and Predicting Breast Cancer Events after Treatment (the UPBEAT trial)

UPBEAT (WF97415) trial info coming soon

July 9, 2018

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

EA8171 trial info here

May 17, 2018

Financial Burden Assessment in Patients with Stage I-III Colon or Rectal Cancer Undergoing Treatment

EAQ162CD trial info here

May 2, 2018

Cisplatin / Carboplatin and Etoposide with or without Nivolumab in Treating Patients with Extensive Stage Lung Cancer

EA5161 trial info here

April 26, 2018

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

EA9152 trial info here

April 13, 2018

Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer

EA2165 trial info here

April 5, 2018

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

EA5162 trial info here

March 28, 2018

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

EA3163 trial info here

March 1, 2018

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

EA5152 trial info here

February 14, 2018

Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab and Paclitaxel

EAE161 trial info here

February 8, 2018

Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated with Docetaxel

EA8153 (CHAARTED2) trial info here

 

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

Robert L. Comis, MD
Group Co-Chair


Mitchell D. Schnall, MD, PhD
Group Co-Chair

 

 

 

 

 

 

img img
img
img